by John-Michael Dumais, Childrens Health Defense:
Moderna halted its Phase 1 trial of an mRNA vaccine to treat the Epstein-Barr virus after a single suspected case of myocarditis in an adolescent, raising questions about the heart-damaging technology used in all mRNA vaccines, according to a report by Alex Berenson.
TRUTH LIVES on at https://sgtreport.tv/
Investigators halted a Moderna trial of a new mRNA vaccine for Epstein-Barr virus (EBV) after a participant developed suspected myocarditis, according to independent journalist Alex Berenson.
Moderna paused the Phase 1 “Eclipse” trial following “an urgent communication” from the company overseeing the trial stating that the adverse event “necessitates an immediate suspension of all dosing for ALL adolescents,” Berenson reported.
A person not employed by Moderna provided the communication to Berenson, a former New York Times reporter and author of 13 books.
The case “will only add to the concerns around mRNA biotechnology and heart issues, particularly myocarditis,” Berenson wrote on Substack. The Moderna and Pfizer mRNA COVID-19 vaccines have been linked to myocarditis, especially in young, healthy males.
Moderna did not disclose the trial halt in public filings, according to Berenson, who suggested financial motivations may be behind the lack of transparency after the company told investors this vaccine was one of several expected to generate billions of dollars.
Moderna’s stock price has dropped nearly 85% from its 2021 highs but still remains one of the most valuable biotech companies with a $30 billion market value.RFK Jr. and Brian Hooker’s New Book: “Vax-Unvax”
The mRNA platform remains the problem
Berenson said the news around the EBV vaccine, which “uses essentially the same design as Moderna’s Covid shot … a strand of modified mRNA surrounded by a tiny fat globule called a ‘lipid nanoparticle’ or LNP,” raises questions about the entire mRNA platform.
He noted that there is lingering uncertainty about whether it’s the spike protein or the lipid nanoparticles used to encapsulate the modified mRNA that causes myocarditis in people who receive the COVID-19 vaccine.
Myocarditis involves inflammation of the myocardium or heart muscle that can lead to cardiac arrest and death. Symptoms can include chest pain, fatigue, difficulty breathing, fever, rash, exercise intolerance and abnormal heart rhythms.
For the COVID-19 vaccines, the observed risk for myocarditis is higher in teenagers and young people than in older adults, according to Berenson.
Berenson referenced a study published in Nature Immunology showing how lipid nanoparticle-formulated mRNA can suppress certain forms of interleukin 1, which can induce elevated cytokine levels and create excessive inflammation.
A March 2022 paper published in Elsevier’s Metabolism Open explored the possible connection between lipid nanoparticles and myocarditis arising from a non-mRNA vaccine.
A 2016 mouse study of mRNA delivered in lipid nanoparticles showed “activity was detectable in the liver, demonstrating systemic spread of the nanoparticles.”
Numerous other studies have linked the COVID-19 mRNA shots to myocarditis.
In June, Berenson reported on the South Korean study of 12 mRNA-driven myocarditis deaths in young adults and nine deaths in adults over 60. The overall vaccine-related myocarditis rate was about 1 in 100,000, with nearly 20% of those cases rated as severe.
The highest rate was reported for males between the ages of 12-17 — 5.29 cases per 100,000. Autopsies revealed a specific inflammatory signature of lymphohistocytes in the myocardium.
Six cases of myocarditis following the administration of the Pfizer mRNA vaccine were reported in a study published in the May 2021 issue of Vaccine, and eight cases of myocarditis were reported in a paper published in the June 2021 issue of Circulation.
Dr. Peter McCullough on Nov. 4 wrote on Substack that the comparative risks of myocarditis and pericarditis with mRNA, adenoviral DNA and spike antigen vaccines, finding that all of these vaccines carried some risk.
Read More @ ChildrensHealthDefense.org
